Lifecome Biochemistry Co Ltd Working Capital to Net Assets Ratio
Lifecome Biochemistry Co Ltd working capital to net assets ratio. Lifecome Biochemistry Co Ltd (002868) has a Working Capital to Net Assets ratio of -479.5% as of June 2026. Working capital of CN¥-346.90 Million (current assets of CN¥199.48 Million minus current liabilities of CN¥546.39 Million) is measured against net assets of CN¥72.35 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 002868 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Lifecome Biochemistry Co Ltd (2012–2025)
Working capital to net assets ratio of Lifecome Biochemistry Co Ltd from 2012 to 2025. This chart shows how Lifecome Biochemistry Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at -479.5%, reflecting working capital of CN¥-346.90 Million against net assets of CN¥72.35 Million CNY. See how many days can Lifecome Biochemistry Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Lifecome Biochemistry Co Ltd Working Capital to Net Assets Ratio by Year (2012–2025)
Lifecome Biochemistry Co Ltd working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Lifecome Biochemistry Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 002868 total asset value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -599.9% | CN¥-389.55 Million | CN¥64.93 Million | CN¥207.68 Million | CN¥597.24 Million | ▼ -4783.5 pp |
| 2024 | 4183.6% | CN¥-1.03 Billion | CN¥-24.54 Million | CN¥216.22 Million | CN¥1.24 Billion | ▲ +4292.7 pp |
| 2023 | -109.1% | CN¥-451.92 Million | CN¥414.11 Million | CN¥478.39 Million | CN¥930.31 Million | ▼ -112.6 pp |
| 2022 | 3.4% | CN¥20.66 Million | CN¥599.30 Million | CN¥505.80 Million | CN¥485.14 Million | ▲ +25.9 pp |
| 2021 | -22.5% | CN¥-162.36 Million | CN¥722.02 Million | CN¥227.97 Million | CN¥390.34 Million | ▼ -45.6 pp |
| 2020 | 23.1% | CN¥177.76 Million | CN¥769.94 Million | CN¥304.58 Million | CN¥126.82 Million | ▼ -34.5 pp |
| 2019 | 57.6% | CN¥448.63 Million | CN¥778.50 Million | CN¥586.27 Million | CN¥137.64 Million | ▼ -1.3 pp |
| 2018 | 59.0% | CN¥436.47 Million | CN¥740.37 Million | CN¥488.22 Million | CN¥51.75 Million | ▼ -5.0 pp |
| 2017 | 64.0% | CN¥445.04 Million | CN¥695.68 Million | CN¥495.92 Million | CN¥50.89 Million | ▲ +59.8 pp |
| 2016 | 4.2% | CN¥11.36 Million | CN¥271.34 Million | CN¥96.81 Million | CN¥85.44 Million | ▲ +18.3 pp |
| 2015 | -14.1% | CN¥-33.67 Million | CN¥238.98 Million | CN¥93.00 Million | CN¥126.67 Million | ▲ +20.7 pp |
| 2014 | -34.8% | CN¥-66.34 Million | CN¥190.87 Million | CN¥97.19 Million | CN¥163.53 Million | ▲ +9.6 pp |
| 2013 | -44.3% | CN¥-75.12 Million | CN¥169.42 Million | CN¥100.22 Million | CN¥175.34 Million | ▼ -16.0 pp |
| 2012 | -28.3% | CN¥-44.26 Million | CN¥156.45 Million | CN¥105.48 Million | CN¥149.74 Million | — |